{
  "pmcid": "12312237",
  "abstract": "250-word version:\n\nTitle: Randomised Controlled Trial to Determine the Maximum Effective Volume of 0.25% Ropivacaine for Superior Trunk Block in Shoulder Arthroscopy\n\nBackground: The superior trunk block (STB) is a promising alternative to interscalene block (ISB) for shoulder arthroscopy, potentially reducing hemidiaphragmatic paralysis (HDP) while maintaining analgesic efficacy. This study aimed to determine the maximum effective volume (MEV90) of 0.25% ropivacaine to prevent HDP in 90% of patients.\n\nMethods: This prospective, randomised controlled trial was conducted at Changzheng Hospital. Participants were adults aged 46-80 years, ASA I-III, scheduled for shoulder arthroscopy. Exclusion criteria included respiratory comorbidities. A biased coin design was used for volume assignment, with randomisation and allocation concealment achieved through sealed envelopes. The primary outcome was HDP occurrence, assessed 3 hours post-block. Blinding was maintained for outcome assessors.\n\nResults: Fifty-two patients were randomised and analysed. The MEV90 of 0.25% ropivacaine for ultrasound-guided STB was estimated at 7.6 mL (95% CI: 6.5â€“8.5 mL) using isotonic regression. No adverse events were reported.\n\nInterpretation: The study identified 7.6 mL as the MEV90 of 0.25% ropivacaine for STB, offering a diaphragm-sparing alternative for patients undergoing shoulder arthroscopy.\n\nTrial registration: Chinese Clinical Trial Registry (ChiCTR2200059042); first registered 23/04/2022.\n\nFunding: Not specified.",
  "word_count": 198
}